Butterfly Network (NYSE:BFLY – Get Free Report) and DexCom (NASDAQ:DXCM – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Butterfly Network and DexCom”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Butterfly Network | $97.61 million | 16.70 | -$77.06 million | ($0.21) | -29.02 |
| DexCom | $4.66 billion | 6.60 | $836.30 million | $2.55 | 32.36 |
Profitability
This table compares Butterfly Network and DexCom’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Butterfly Network | -43.56% | -21.60% | -14.25% |
| DexCom | 19.42% | 37.77% | 15.98% |
Volatility & Risk
Butterfly Network has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Butterfly Network and DexCom, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Butterfly Network | 1 | 1 | 5 | 1 | 2.75 |
| DexCom | 0 | 2 | 24 | 2 | 3.00 |
Butterfly Network currently has a consensus price target of $8.75, indicating a potential upside of 43.56%. DexCom has a consensus price target of $95.50, indicating a potential upside of 15.73%. Given Butterfly Network’s higher possible upside, equities analysts clearly believe Butterfly Network is more favorable than DexCom.
Institutional and Insider Ownership
37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 22.0% of Butterfly Network shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
DexCom beats Butterfly Network on 11 of the 15 factors compared between the two stocks.
About Butterfly Network
Butterfly Network develops portable ultrasound technology for healthcare professionals. Its handheld devices use the company’s semiconductor-based Ultrasound-on-Chip technology to produce ultrasound images and connect with compatible mobile devices, offering an alternative to larger, cart-based systems. The company’s products include the Butterfly iQ line of handheld ultrasound devices, along with software and cloud-based tools for viewing, managing and sharing medical images. Its offerings are designed for use across a range of clinical settings and applications.
About DexCom
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
Receive News & Ratings for Butterfly Network Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Butterfly Network and related companies with MarketBeat.com's FREE daily email newsletter.
